At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 33 enrolled
Drug / intervention
Placebo +1 moredrug
Likely dose
NVA237 50 μgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-blind, Placebo-controlled, Multi-center, Two-period Crossover Study to Investigate the Bronchodilatory Effect of 50 µg NVA237 Inhaled Once Daily in Patient With Chronic Obstructive Pulmonary Disease (COPD).
In Brief
A Phase 2 clinical trial evaluating Placebo and NVA237 for Chronic Obstructive Pulmonary Disease. Completed, enrolled 33 participants across 2 sites in 2 countries.
Detailed Summary
This study was intended to assess how well inhaled NVA237 opens up the airways of patients with mild, moderate or severe COPD over a 24 hour period after a 14 day treatment period.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChronic Obstructive Pulmonary Disease
CountriesGermany, United States
Collaborators--
Timeline
Phase 2CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartFeb 2009
First PostedMar 2009
Primary CompletionMay 2009
TodayJul 2026
First PostedMar 5, 2009
Enrollment StartFeb 1, 2009
Primary CompletionMay 1, 2009
TodayJul 2, 2026
Enrollment to primary: 3 monthsPosted 17.3 years ago
Interventions
Placebodrug
Matching placebo capsules were supplied for inhalation once daily with Concept 1 device.
NVA237drug
NVA237 50 μg capsules were supplied for inhalation once daily with Concept 1 device.